Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | ALB | P02768 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.49 |
| ▸ | PNP | P00491 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.47 |
| ▸ | ADA | P00813 | 1/20 | 0.44 |
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25712959 | 0.88 | LMNA (0.59) | LMNAALDH1A1ALBMAPK1CYP1A2 | |
| SCHEMBL3239663 | 0.88 | LMNA (0.59) | LMNAALDH1A1ALBMAPK1CYP1A2 | |
| SCHEMBL7435133 | 0.87 | LMNA (0.58) | LMNAALDH1A1ALBMAPK1CYP1A2 | |
| SCHEMBL3054167 | 0.86 | LMNA (0.58) | LMNAALDH1A1ALBMAPK1CYP1A2 | |
| SCHEMBL22862138 | 0.86 | LMNA (0.58) | LMNAALDH1A1ALBMAPK1CYP1A2 | |
| SCHEMBL23641839 | 0.86 | LMNA (0.54) | LMNAALDH1A1ALBMAPK1CYP1A2 | |
| SCHEMBL2808298 | 0.86 | LMNA (0.58) | LMNAALDH1A1ALBMAPK1CYP1A2 | |
| SCHEMBL30694424 | 0.86 | LMNA (0.65) | LMNAALDH1A1ALBMAPK1CYP1A2 | |
| SCHEMBL9601706 | 0.86 | LMNA (0.57) | LMNAALDH1A1ALBMAPK1CYP1A2 | |
| SCHEMBL8124562 | 0.86 | LMNA (0.65) | LMNAALDH1A1ALBMAPK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071101-A1 | Nucleoside Phosphonate Analogs | BOOJAMRA CONSTANTINE G | 2011-03-24 | — | — | US | disclosed |
| US-20100290990-A1 | METHOD FOR PREPARING A MARKED PURINE DERIVATIVE, SAID DERIVATIVE AND USES THEREOF | BARRE LOUISA | 2010-11-18 | — | — | US | disclosed |
| US-7807685-B2 | Therapeutic compounds | CBT DEVELOPMENT LIMITED (GB) | 2010-10-05 | — | — | US | disclosed |
| US-20080076776-A1 | Therapeutic compounds | BIOVITRUM AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-20070142317-A1 | Topical composition for treatment of skin disorders | QLT USA, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| WO-2005065668-A2 | TOPICAL COMPOSITIONS COMPRISING HALO-DEOXYADENOSINES FOR TREATMENT OF SKIN DISORDERS | QLT USA, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| US-5013829-A | Stable congener of 2',3'-dideoxyadenosine | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1991-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142317-A1 | Topical composition for treatment of skin disorders | CDA, ADA, DCTD | LMNA 3214/4885ALDH1A1 620/4885ALB 1342/4885 |
| US-20110071101-A1 | Nucleoside Phosphonate Analogs | TYMP, PNP, NUDT1 | LMNA 1265/4885ALDH1A1 3413/4885ALB 3364/4885 |
| US-20080076776-A1 | Therapeutic compounds | FPR3, OGFR, OPRK1 | LMNA 3103/4885ALDH1A1 2186/4885ALB 2034/4885 |
| US-20100290990-A1 | METHOD FOR PREPARING A MARKED PURINE DERIVATIVE, SAID DERIVATIVE AND USES THEREOF | TPMT, NUDT1, DUT | LMNA 3403/4885ALDH1A1 341/4885ALB 2847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.